Quick Answer
SUTRO BIOPHARMA, INC. reported Operating Income of -$158.37 million for fiscal year 2025.
SUTRO BIOPHARMA, INC. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$158.37M | +33.6% |
| 2024 | -$238.45M | -167.1% |
| 2023 | -$89.28M | +30.8% |
| 2022 | -$128.94M | -30.9% |
| 2021 | -$98.52M | -38.7% |
| 2020 | -$71.06M | -28.1% |
| 2019 | -$55.47M | -49.0% |
| 2018 | -$37.22M | -93.1% |
| 2017 | -$19.27M | -1512.9% |
| 2016 | $1.36M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$48.46M | +28.7% | -1348.7% |
| June 30, 2025 | -$3.35M | +93.1% | +95.1% |
| March 31, 2025 | -$68.51M | -21.1% | -0.9% |
| September 30, 2024 | -$67.92M | -54.3% | -39.5% |
| June 30, 2024 | -$48.69M | -5.4% | +14.0% |
| March 31, 2024 | -$56.59M | -34.0% | -28.6% |
| September 30, 2023 | -$44.01M | -107.5% | +4.7% |
| June 30, 2023 | -$46.18M | -138.3% | -9.3% |
- SUTRO BIOPHARMA, INC. showed an increase of +33.6% in Operating Income compared to the prior fiscal year.
- Over the 2016–2025 period, SUTRO BIOPHARMA, INC.’s operating income has declined by 11710.5% (from $1.36 million to -$158.37 million).
- The most recent figure is from SUTRO BIOPHARMA, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: